|Bid||107.80 x 800|
|Ask||107.81 x 800|
|Day's Range||107.51 - 108.72|
|52 Week Range||95.27 - 116.49|
|PE Ratio (TTM)||18.56|
|Earnings Date||Oct 17, 2018 - Oct 22, 2018|
|Forward Dividend & Yield||2.00 (1.85%)|
|1y Target Est||116.86|
In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.
Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues. It is characterized by a high volume of relatively low-dollar transactions. Under DIS, Quest provides clinical testing and other services. Major customer groups for DIS include healthcare insurers, government payers, client payers, and patients.
Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.
Quest Diagnostics generated net income of $219.0 million in the second quarter of 2018 as compared with net income of $193.0 million in the second quarter of 2017, which translated into net earnings per share of $1.57 in the second quarter of 2018.
Creditors of Provant Health Solutions are moving to stop both an initial bid and continued financing for the bankrupt company, saying other potential buyers will be discouraged by the process and that too little cash is budgeted to investigate claims. Provant, based in Olathe, Kan., provides services that include sample collection, health-risk screening and on-site flu shots administered by independent contractors. Inc., which does business as Provant, objected to Quest’s lead bid and the protections afforded the company as the so-called stalking horse bidder.
Tough competitive landscape and reimbursement issues are major deterrents to Quest Diagnostics' (DGX) top line in the near term. The company's focus on promising areas to drive growth is a positive.
SECAUCUS, N.J., Sept. 7, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City. Stephen Rusckowski, Chairman, President and CEO and Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
SECAUCUS, N.J., Sept. 6, 2018 /PRNewswire/ -- More than half (52 percent) of Americans tested in 2017 misused their prescription drugs, the same rate as in 2016, but the epidemic is shifting beyond prescription opioids to encompass other drugs and dangerous drug combinations, finds a new Health Trends™ report released today by Quest Diagnostics (DGX): Drug Misuse in America 2018.
The blood-testing company, based most of its life in Palo Alto, has faced lawsuits from investors, the SEC and criminal charges against founder and former CEO Elizabeth Holmes and former President Ramesh "Sunny" Balwani.
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to start learning about core conceptsRead More...
Provant, based in Olathe, Kan., provides services that include sample collection, health-risk screening and on-site flu shots administered by independent contractors. Provant said it has 326 employees on its payroll but through a network of health professionals did nearly 1 million screenings last year. In 2017, Hooper, founded in 1899, merged with Provant Health Solutions LLC. Hooper and its subsidiaries now do business as Provant Health.
SECAUCUS, N.J. , Aug. 17, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly ...
SECAUCUS, N.J., Aug. 16, 2018 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced that it achieved gold status in the American Heart Association's 2018 Workplace Health Achievement Index, ranking the company's workplace health program among the best in the nation. The American Heart Association created the Index with its CEO Roundtable members, a leadership collaborative of more than 40 CEOs from some of America's largest companies who are committed to applying evidence-based approaches to improve their employees' overall health. The Index uses science-based best practices to evaluate the overall quality and comprehensiveness of their workplace health programs.
The New York Giants and Quest Diagnostics are now focusing on creating hydration plans for each player.
Court documents give some insight into one of the biggest questions about Theranos: How could its board stand pat as key employees left and allegations emerged about the blood testing company's technology?
On Monday, July 30, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended Monday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Laboratories & Research equities this morning: Agilent Technologies Inc. (NYSE: A), Co-Diagnostics Inc. (NASDAQ: CODX), Quest Diagnostics Inc. (NYSE: DGX), and Bruker Corp. (NASDAQ: BRKR).
- Number of positive tests for Lyme disease increased significantly between 2016 and 2017. - Historically concentrated in Pennsylvania and New England states, Lyme disease has been detected in each of the 50 United States and the District of Columbia. - Outside of the northeastern U.S., California and Florida - states not historically associated with significant rates of Lyme disease - saw the largest absolute increases in positive Lyme disease test results.
There's been a lot of talk on the Street about the biotech sector and how drug makers haven't been bringing the heat in 2018. Just six biotech company IPO launches hit this last week. Two new biotech companies are poised to go public this week.
The S&P 500’s top losses on July 24 were: Whirlpool (WHR) declined 14.52%. Quest Diagnostics (DGX) declined 8.24%. Nektar Therapeutics (NKTR) declined 5.89%. Hasbro (HAS) declined 4.65%. Centene (CNC) declined 4.5%. Whirlpool